The Death of the ‘Testosterone Causes Prostate Cancer’ Myth: What Every Man on HRT Needs to Know

madman · Jun 30, 2026

Thread 'Helen L. Bernie, DO, MPH, on counseling patients through TRT and prostate cancer uncertainty'

Jun 30, 2026

The FDA's proposed narrowing of the testosterone therapy prostate cancer contraindication to metastatic disease only reflects current clinical evidence, opening the door to testosterone therapy in appropriately selected men with treated localized prostate cancer or on active surveillance, with shared decision-making and PSA-testosterone co-monitoring as the foundation of responsible care, as Helen L. Bernie, DO, MPH, outlines in this interview.

madman · Jul 6, 2026

Thread 'FDA's Newest Testosterone Update | What Men Need to Know'

Jul 6, 2026

In this episode, Dr. Brandon and Dr. Morgentaler talk about the FDA's groundbreaking testosterone label changes, the evolving evidence on testosterone therapy and prostate cancer, and how quality of life should factor into treatment decisions for men with advanced disease.

Time stamps:

00:00 Listener Question Metastatic Prostate Cancer – Dr. Morgentaler explains whether testosterone or anabolic steroids may have a place in treating men with metastatic prostate cancer while preserving quality of life.

04:09 Testosterone Quality of Life...

madman · Jul 11, 2026

Thread 'Treatment of Prostate Cancer: Testosterone and PCa - From Dogma to Data'

Jul 11, 2026

Helen L. Bernie, DO, MPH, Director, Sexual and Reproductive Medicine and Assistant Professor of Urology, Indiana University, Carmel, Indiana, presents a review of testosterone therapy in men with prostate cancer, focusing on current evidence and clinical management.

She examines the historical belief that testosterone promotes prostate cancer progression and traces this concept to early studies with limited data. Contemporary evidence is reviewed, including observational studies, retrospective analyses, and randomized trial data evaluating the safety of...

madman · Aug 6, 2026

Thread 'Neil Baum, MD, and Abraham Morgentaler, MD, discuss the history of testosterone and prostate cancer'

Aug 6, 2026

Neil Baum, MD, and Abraham Morgentaler, MD, discuss the history of testosterone and prostate cancer | Urology Times

Abraham Morgentaler, MD, joins Neil Baum, MD, to discuss the historical origins of the belief that testosterone drives prostate cancer and the new framework presented in his recent Journal of Urology publication.

www.urologytimes.com

Abraham Morgentaler, MD, joins Neil Baum, MD, to discuss the historical origins of the belief that testosterone drives prostate cancer and the new framework presented in his recent Journal of Urology publication.

madman · Aug 28, 2026

Thread 'Miller School Trial Tests Testosterone Therapy in Men With Low-Risk Prostate Cancer'

Aug 28, 2026

* “Active surveillance is about safely managing low-risk prostate cancer while preserving quality of life,” said Sanoj Punnen, M.D., professor of urologic oncology at the Miller School and DSUI vice chair of research. “For some men, maintaining quality of life may include testosterone supplementation. While historical dogma raised concerns about testosterone use in men with prostate cancer, many urologists now believe it can be used safely in carefully selected men on active surveillance with appropriate monitoring. The challenge is that we still lack...

madman · Sep 5, 2026

madman said:
Eye opener here!

Abraham Morgentaler

* This is a misleading way of presenting it and this is my own slide so I'll take responsibility. The problem is that there is no occurrence in actual life where a mature male has a testosterone of. zero without a previous intervention and the better way to present this is to show decraesing serum testosterone

Saturation Model
View attachment 55813
View attachment 55812

Thread 'T Does Not Drive Prostate Cancer: Presenting the New Framework of Androgen Adequacy vs Inadequacy'

Sep 5, 2026

Two heavy weights in the field drop a big one!

* Sixty-five years after the landmark publication by Huggins and Hodges, it was discovered that their principal conclusion that T injections “activated” PCa even in hormonally intact men was based on erratic acid phosphatase results in a single patient treated for only 18 days. 18

* In 2009, we presented the Saturation Model 8 as a new paradigm that resolved the paradox in which androgen deprivation therapy (ADT) provided clinical benefits in metastatic PCa, yet TTh failed to demonstrate adverse PCa outcomes...

madman · Sep 19, 2026

Thread 'Testosterone replacement therapy in Prostate cancer (Part 2)'

Sep 19, 2026

Dr. Samantha Strumeier

* There's absolutely no evidence that testosterone replacement therapy causes prostate cancer, there's a lack of long-term data but I think you know we have a lot more data keeps coming out over the years and we should really hone in on that

Episode 114: Testosterone replacement therapy in Prostate cancer with Dr Samantha Strumeier - Simply Oncology

Welcome back for our second of this 2 part special on testosterone in cancer with the excellent Dr Samantha Strumeier from Barts health NHS trust.Did you know that 10% of patients can end up with ongoing testosterone suppression after comple...

simplyoncology.buzzsprout.com

Welcome back for our second of this 2 part special on testosterone in cancer with the excellent Dr...